Abstract Recently, colorectal cancer (CRC) subtyping consortium identified four consensus molecular subtypes (CMS1-4). CMS1 is enriched for deficient mismatch repair (dMMR) and BRAF V600E tumors. Intriguingly, this subtype has better relapse-free survival but worse overall survival after relapse compared with the other subtypes. Growing evidence is accumulating on the benefit of specific therapeutic strategies such as immune checkpoint inhibition therapy in dMMR tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in tumors harboring BRAF V600E mutation. After reviewing dMMR prognostic value, immune checkpoints as major targets for dMMR carcinomas will be highlighted. Following, BRAF V600E prognostic impact will be reviewed and therapeutic strategies with the combination of cytotoxic agents and especially the combinations of BRAF and MAPK inhibitors will be discussed.
Introduction
Colorectal cancer (CRC) is a biologically heterogeneous disease that arises through distinct pathways including chromosomal instability (CIN), microsatellite instability (MSI), and CpG island methylator phenotype (CIMP). CIMP phenotype, with some degree of overlap with CIN and MSI, represents a specific type of epigenetic instability that leads to aberrant gene silencing [1] . MSI phenotype is caused by deficient DNA mismatch repair (dMMR) function resulting from an epigenetic inactivation of MLH1 or from a germline mutation of one of the MMR genes (MLH1, MSH2, MSH6, and PMS2) predisposing to the Lynch' syndrome (LS).
Sporadic dMMR CRC, but not LS, is frequently associated with the v-raf murine sarcoma viral oncogenes homolog B1 (BRAF) V600E mutation. Replacement of valine by glutamic acid at position 600 within BRAF gene makes mutant BRAF protein constitutively active, inducing activation of MAP kinase pathway through the phosphorylation of mitogen-activated protein kinase (MEK) downstream. Colorectal cancer subtyping consortium (CRCSC) identified four distinct consensus molecular subtypes (CMSs) of CRC based on genetic and epigenetic analyses [2, 3] . CMS1 includes dMMR and/or BRAF V600E CRC and is associated with proximal location, immune activation, older age at diagnosis, and female gender. CMS2 tumors exhibit high CIN, proficient MMR (pMMR), P53 mutation, and/or WNT/MYC pathway; tumors with low CIN, KRAS mutation, and/or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutation fall in CMS3. CMS4 tumors are characterized by transforming growth factor (TGF)-beta and/or vascular endothelial growth factor (VEGF) pathway activation and associated with mesenchymal phenotype and younger age at diagnosis. CRC with dMMR and/or BRAF V600E represent subtype with a poor survival after relapse (SAR) despite a favorable disease-free survival (DFS) among the four subtypes [2] . Interestingly, dMMR CRC has been recently shown as an attractive target of immunotherapy [4••] .
This review is focused on dMMR and BRAF V600E in metastatic CRC (mCRC). In the first part, a comprehensive overview of prognostic impact of dMMR status and of recent data of immune checkpoint modulation for dMMR mCRC is provided. In the second part, prognostic and predictive values of BRAF V600E mutation are presented followed by an update of the clinical results of targeted therapeutic strategies for BRAF V600E mCRC.
Mismatch Repair Deficiency Early Stage Colorectal Cancer
Colorectal tumors with dMMR can be detected through immunohistochemistry or polymerase chain reactionbased assay (Box 1). This tumor type is commonly associated with proximal location, high-grade mucinous differentiation, and prominent lymphocyte infiltration [5] . Data show that dMMR status confers improvement DFS in patients with stage II or III CRC [6] [7] [8] and that 5-fluorouracile (5-FU)-based chemotherapy is ineffective in patients exhibiting stage II dMMR tumors [6, 7, 9] . Other studies have shown that in patients with high-risk stage II and stage III tumors who received oxaliplatinbased adjuvant chemotherapy (i.e., FOLFOX), dMMR status conferred DFS benefit (André et al., in press, Journal of Clinical Oncology 2015) [10, 11] . Interes tingly, Collura et al. showed that large biallelic deletion in the T17 intron of the gene that encodes chaperone protein HSP110 sensitizes CRC to 5-FU alone or 5-FU plus oxaliplatin in the adjuvant setting and affect survival of patients with stages II and III tumors [12, 13] . Given that this mutation confers an important fraction (about 25 %) of patients with stage II and III dMMR CRC, these findings lead to reflection of the genetic feature importance in chemosensitivity analysis of these tumors. [17] . This method is comparing the differences in allelic sizes obtained from tumor and normal DNA, MSI being defined by instability for at least two of the five microsatellites. However, the Bethesda panel has several limitations, mainly due to the difficulty to interpret PCR amplification of dinucleotide markers. Therefore, the revised Bethesda guidelines recommend the use of mononucleotide repeats instead of dinucleotide repeats [18] . An alternative pentaplex-PCR assay comprising five quasi-monomorphic mononucleotide repeats (BAT-26, BAT-25, NR-21, NR-24, and NR-27) has been developed, MSI status being defined by the instability of three microsatellites or more. This optimized pentaplex PCR assay (Pentaplex Promega © ) is at least as sensitive and specific for detection of MSI status as the Bethesda panel and obviate the need for normal matching DNA for comparison [14] .
Metastatic Colorectal Cancer
The impact of dMMR status on survival of patients with CRC has not been fully elucidated. The poor prevalence of dMMR in patients with mCRC (3-5 %) reinforces the low metastatic capacity of dMMR tumors and hampers the evaluation of dMMR status as a prognostic biomarker in mCRC. Indeed, the results from early studies of microsatellite instability and BRAF mutation on survival in mCRC remain inconclusive or inconsistent [19] [20] [21] [22] . However, the pooled analysis of four phase III studies in first-line treatment of mCRC, the CAIRO, CAIRO2, COIN, and FOCUS studies, by [23••] . The authors also suggested that the worse prognostic value observed in BRAF V600E tumors may be related to the pattern of metastatic spreading. Indeed, the low frequency of liver metastasis [22] and high rate of peritoneal disease [24] have been reported in dMMR tumors.
Therapeutic Perspectives for Treatment of dMMR mCRC
The immune checkpoint therapeutic strategies, such as inhibition of anti-programmed death 1 (PD-1) receptor or its ligand (PD-L1), can be considered really breakthrough agents in the targeted treatment of dMMR mCRC. A recently published phase II trial showed that patients with dMMR CRC (N = 11) are more responsive to anti-programmed death 1 (PD-1) antibody pembrolizumab than are pMMR CRC pa-
The immune-related objective response rate and the 20-week immune-related PFS rate were 40 and 78 % for dMMR mCRC versus 0 and 11 % for pMMR mCRC, respectively. According to immune-related response criteria, new lesions did not constitute disease progression if tumor burden, including new lesions, was stable or decreased. Hazard ratio for PFS was 0.10 (P < 0.001) and for OS was 0.22 (P = 0.05). Results in patients with dMMR non-CRC (N = 9) were similar to those with dMMR tumors. Interestingly, whole-exome sequencing analysis of dMMR and pMMR tumors revealed 20-fold more somatic mutations (inducing much more tumor-specific neoantigens) in dMMR CRC as compared with pMMR CRC [4••, 25] . These results suggested that specific immune response elements are linked to tumor genomics; that is, dMMR tumors may be much more responsive to checkpoint blockage with anti-PD-1 due to their incapacity to repair DNA mismatches. Higher tumor neoantigen load was associated with tumor-infiltrating lymphocytes and improved survival outcomes [26, 27] .
These data along with the previous observation of dense immune infiltration in those tumors support the hypothesis that dMMR CRC may be an attractive target for immunotherapy [5] . Galon and colleagues first established that the immune context as defined by the type, the density, and the location of immune cells in CRCs has the prognostic value, highlighting T-helper (Th)1-related adaptive immunity (characterized by interferon-γ production) [28] [29] [30] . This finding was confirmed by Lal et al. on an immune gene signature which delineated dMMR CRC as a specific subgroup exhibiting high expression of Th1-related immune genes and immune checkpoint-related genes [31] . Interestingly, this active immune microenvironment is counterbalanced by the overexpression of several immune checkpoint genes including PD-1, PD-L1, cytotoxic T lymphocyte antigen 4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), and indoleamine 2,3-dioxygenase (IDO) [32•] , making sense of immune checkpoint inhibition in dMMR CRC.
The remarkable efficacy of pembrolizumab in dMMR CRC reported in phase II study by Le et al. is an exciting discovery that opens up an entirely new field of investigations [4••] . One must keep in mind that this was a very small trial where median PFS and OS for dMMR cohorts were not reached after a median follow-up of 36 weeks; thus, larger study will be needed to confirm the findings and clarify specific issues such as effect on OS and PFS in dMMR cohort. Of note, PD-L1 expression within tumor or microenvironment was not significantly associated with either better PFS or OS. Further studies are needed to explore the PD-1 and PD-L1 expressions and tumor-infiltrating immune cells as potential biomarkers of efficacy in dMMR mCRC. A phase II clinical trial of nivolumab (another anti-DP-1 antibody) and nivolumab plus ipilimumab in patients with dMMR mCRC is ongoing (ClinicalTrials.gov identifier NCT02060188). Moreover, the relation between BRAF V600E status and efficacy of immune checkpoints inhibition in sporadic cancers with dMMR also warrants further exploration. Combining immunotherapy with targeted therapy in BRAF V600 dMMR mCRC may be an interesting approach which should be investigated. Finally, immune checkpoint inhibitors should be evaluated for efficacy in patients with constitutional MMR deficiency syndrome (CMMRD). CMMRD, variant of LS, is a rare condition that results from bi-allelic germline mutations of the MMR genes and is associated with a broad spectrum of childhood cancers, including CRC, hematologic malignancies, and brain tumors [33] .
BRAF-Mutated Colorectal Cancer
The serine/threonine-protein kinase BRAF is a downstream signaling protein in the epidermal growth factor receptor (EGFR)-mediated mitogen-activated protein kinase (MAPK) pathway that exerts its oncogenic effect through the induced phosphorylation and activation of MEK. As with RAS mutations, mutation of codon 600 within the activation segment of the kinase domain of BRAF causes constitutive activation of the MAPK pathway. Approximately 10 % of CRC are BRAF-mutated, with V600E mutation in 87-93 % of cases. The V600E BRAF-mutated CRCs are located predominantly in the right side of the colon, in older women, and typically arise from serrated adenomas and exhibit high grade of differentiation. BRAF V600E mutation is strongly associated with dMMR (20-70 % of dMMR tumors vs 5-10 % of pMMR tumors) [23••, 34] and indicates a sporadic origin [35] . The gold standard for diagnostic analysis of a BRAF V600E mutation is currently direct sequencing. H o w e v e r, t h e cl i n i c a l i m p a c t o f t h e ve r y ra r e non-BRAF V600E mutations, such as BRAF codons 594 and 596 mutations, has been infrequently evaluated. The analysis of ten patients with mCRC harboring BRAF codon 594-or 596-mutated tumors suggested different pathological characteristics and clinical outcomes from these of BRAF V600E tumors [36] . Longer OS was reported in patients with BRAF codon 594-or 596-mutated tumors when compared with BRAF V600 -mutated CRCs (median OS 62.0 vs 12.6 months; hazard ratio 0.36 (95 % confidence interval 0.20-0.64), P = 0.002).
Prognostic Impact of BRAF V600E Mutation in Early CRC
The BRAF V600E mutation is present in 6-15 % [8, [37] [38] [39] [40] [41] . Analyses of the QUASAR study, Intergroup 0-135, and MOSAIC trials data did not show any significant prognostic impact of BRAF status on DFS (André et al., in press, Journal of Clinical Oncology 2015) [8, 41] . In a pooled analysis of the NSABP C-07 and C-08 trials, BRAF V600E mutation was associated with poor OS (HR 1.46, P < 0.0002) and poor SAR (HR 2.31 P < 0.0001) and not DFS (HR, 1.02, P = 0.86) [42] . The translational study on the PETACC-3, EORTC 40993, and SAKK 60-00 trials showed that BRAF tumor V600E mutation significantly decrease OS in patients with pMMR tumors (HR 2.2, P = 0.0003) [37] . Furthermore, a pooled analysis of a large cohort of 3934 patients with pMMR stage III CRC from the PETACC-8 and N0147 trials showed that BRAF V600E was an independent predictor of shorter time to recurrence, SAR, and OS [43] . These results strongly suggest that BRAF V600E mutation is associated with poor prognosis in patients with pMMR tumors. However, the positive prognostic impact of dMMR status in stages II and III CRCs seems not significantly related to the presence of BRAF V600E mutation. The strong inter-relation between BRAF V600E mutation and dMMR status is particularly interesting, given that these two biomarkers exhibit opposite prognostic effects in mCRC. Thus, dMMR status may reduce the risk of recurrence induced by BRAF
V600E
CRCs, but its positive prognostic value may be eclipsed by the impact of BRAF V600E after relapse, explaining the association of BRAF V600E mutation with SAR and OS but not with DFS.
Prognostic Impact of BRAF
V600E Mutation in mCRC BRAF V600E is associated with a higher frequency of peritoneal and distant lymph node metastases and a decreased lower rate of lung metastases compared to BRAF wild-type tumors (BRAF WT ) [22, 24] . This distinct pattern of metastatic spread may be a possible explanation for the poor prognostic impact of BRAF V600E in mCRC. Indeed, the analyses of the NSABP C-07 and C-08 trials reported by Gavin et al. clearly showed that BRAF V600E was associated with poor prognosis after relapse in stages II and III CRC [42] . In a pooled analysis of the CAIRO, CAIRO-2, COIN, and FOCUS trials, prevalence of BRAF V600E was 8.2 % in mCRC [23••] . Median PFS and OS were significantly reduced for patients with BRAF V600E compared with BRAF W T tumors (HR 1.34, P < 0.001 vs HR 1.91, P < 0.001). In pMMR mCRC stratified by BRAF V600E status, the median OS was significantly decreased in patients with BRAF V600E compared to those with BRAF WT tumors (11.3 vs 17.3 months; HR 1.94, P < 0.001). In dMMR mCRC, no statistically significant difference was observed for OS between two groups of patients (11.7 [8, 37] . The observed increase of prevalence between localized and advanced dMMR CRC reinforces BRAF V600E mutation as a significant poor prognostic factor in dMMR tumors.
Predictive Impact of BRAF V600E Status in mCRC
Constitutively active BRAF V600E mutations are almost always mutually exclusive of KRAS mutations. The activating mutations in KRAS induce constitutive Ras/MAPK signaling, which cannot be suppressed by EGFR inhibition. It has been suggested that BRAF V600E may be predictive of resistance to anti-EGFR monoclonal antibody therapies, although this association remains controversial, but its negative predictive prognostic value has been established. The analysis of patients with BRAF V600E mCRC of the CRYSTAL phase III trial showed no significant difference but a trend of better PFS or OS between patients treated with FOLFIRI alone and FOLRIRI plus cetuximab in first-line setting (HR 0.93, 95 % CI 0.42-2.06; HR 0.91, 95 % CI 0.51-1.62) [44] . Similar results were observed in the PRIME and FIRE-3 phase III trials [45] [46] [47] . Anti-EGFR monoclonal antibody survival benefit was observed in patients with BRAF V600E tumors ( Table 2 ). In pre-treated BRAF V600E mCRC, BRAF V600E status did not discriminate between responders and non-responders to anti-EGFR therapy [48] [49] [50] [51] [52] . In addition, there is insufficient evidence to conclude that patients with mCRC do not benefit from anti-EGFR monoclonal antibody in the presence of BRAF V600E as shown in the meta-analysis of randomized controlled trials of CRC patients reported by Rowland and colleagues [53•] . Based on these findings, there is yet no sufficient data that would justify the exclusion of anti-EGFR monoclonal antibody therapy for patients with RAS WT / BRAF V600E mCRC.
Targeting BRAF V600E mCRC
Considering that patients with BRAF V600E mCRC have a lower probability of receiving further lines of chemotherapy because of their poor prognosis [54] , further intensification of standard therapy may be a pragmatic and an efficient therapeutic approach to overcome this issue. The intensification of the treatment with the triplet regimen FOLFOXIRI (5-FU, leucovorin (LV), oxaliplatin, and irinotecan) in combination with bevacizumab has been evaluated for chemotherapy-naive CRC patients in phases II and III studies with encouraging results [55] [56] [57] [58] 59 •]. In the phase II study by Masi et al., median PFS was 12.8 months and OS was 23.8 months for FOLFOXIRI/bevacizumab in BRAF V600E -mutated patients (N = 10) [55] . The addition of bevacizumab to FOLFOXIRI regimen increased treatment efficacy in the a pooled analysis of 25 BRAF V600E patients reported by Salvatore and colleagues [56] . At a median follow-up of 34.1 months, the pooled set of patients showed a median PFS of 11.8 months and a median OS of 23.8 months. In the phase III TRIBE trial, patients were randomized either to FOLFOXIRI/bevacizumab or FOLFIRI/bevacizumab. In this study, patients with BRAF V600E mCRC showed a non-significant increase of OS when treated with FOLFOXIRI/bevacizumab (19 vs 10.7 months; HR 0.54, 95 % CI 0.24-1.20). FOLFOXIRI/ bevacizumab treatment was tolerable with 8.8 % febrile neutropenia and 18.8 % grade 3-4 diarrhea [57, 58, 59 •]. These data suggest that FOLFOXIRI plus bevacizumab is a serious and valid option for the first-line treatment of chemotherapynaive fit patients with BRAF V600E mCRC. Vemurafenib, an oral inhibitor of the mutant BRAF kinase, achieved minimal clinical activity in BRAF V600E -advanced melanoma patients, showing a significant benefit in response rates, PFS, and OS [60, 61] . However, vemurafenib alone achieved minimal clinical activity in BRAF V600E mCRC patients [62] . Prahallad and colleagues demonstrated that BRAF V600E inhibition causes a rapid feedback activation of EGFR in CRC cell lines [63••] . Based on this observation, the combination of vemurafenib with an anti-EGFR therapy or a MEK inhibitor may be more effective way to overpass BRAF inhibitor primary resistance in BRAF V600E mCRC in the clinical setting. Two recent studies showed that the combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib significantly improved OS in patients with BRAF V600E metastatic melanoma. The combination significantly improved OS compared with single-agent inhibition [64, 65] . Moreover, dual BRAF-MEK inhibition by dabrafenib and trametinib was shown to reduce the single-agent cutaneous toxicities probably due to their opposing effects on cellular functions and signaling. In cells expressing BRAF WT such as epidermal keratinocytes, BRAF inhibitors binding to one member of RAF homo/heterodimers inhibit one promoter but paradoxally transactivate the drugfree protomer, which results in increased downstream the RAF-MEK-ERK signaling, while the combination of EGFR and MEK inhibitors effectively block the MAPK signaling pathway [66, 67] . Several drug combinations are currently tested in BRAF V600E mCRC (Table 3) . Combined inhibition with dabrafenib and trametinib showed limited activity in BRAF V600E stage IV mCRC with a response rate of 12 %, including one prolonged complete response (>22 months) in phase I/II trial [71] . The further logical next step for treatment optimization was the Bhorizontal^and Bvertical^inhibition of MAPK pathway with the triplet therapy including dabrafenib, trametinib, and panitumumab [72] . Atreya et al. conducted phase I/II trial of this combination in BRAF-mutated mCRC. Overall, 11, 36, and 54 % of patients treated with the combination of panitumumab and dabrafenib, the triple regimen, and the combination of trametinib plus panitumumab, respectively, required dose reductions or interruptions. The greatest proportion of serious dermatologic toxicities with the combination of panitumumab and trametinib without the BRAF inhibitor were reported; thus, that addition of dabrafenib to the doublet lessened skin-related toxicity. Overall, 26 % of confirmed response rates with one confirmed complete response were observed [72] . The triplet therapy therefore appears to be more active in BRAF V600E mCRC than the double combination of BRAF and MEK inhibitors but is associated with significant skin toxicities. The combination of panitumumab with vemurafenib for BRAF V600E mCRC has shown interesting hints of enhanced clinical activity in a pilot trial by Yaeger et al. [69] . Two of 12 evaluable patients (13 %) had confirmed long-lasting partial responses. The combination was well tolerated with less cutaneous toxicity than expected with either agent. The activity of the triplet combination of vemurafenib with cetuximab and irinotecan for the treatment of 19 BRAF-mutated mCRC was evaluated in a phase Ib trial [70] . The majority of patients (74 %) had received prior irinotecan and nearly half had prior exposure to cetuximab. Confirmed response rate was 53 % and median PFS was 7.7 months. These results form the basis for the ongoing phase 2 Intergroup Study S1402 trial of irinotecan and cetuximab w ith or w ithout vemurafenib i n cetuximab-naive BRAF V600E patients (ClinicalTrials.gov identifier NCT02164916). MO29112 is an ongoing phase II trial evaluating a biomarker-driven maintenance strategy for FOLFOX plus bevacizumab first-line therapy in patients with BRAF V 6 0 0 E mCRC (ClinicalTrials.gov identifier NCT02291289). Patients with BRAF V600E mCRC without progressive disease after induction with the FOLFOX plus bevacizumab combination are randomized to receive either 5 -F U / LV w i t h c e t u x i m a b a n d v e m u r a f e n i b o r fluoropyrimidine (5-FU/LV or capecitabine) plus , clinical trial enrollment should be systematically considered and planned so that patients with tumors harboring this mutation have the opportunity to receive these innovative-targeted therapies.
Conclusion
Given the high frequency of CRC worldwide, dMMR and BRAF V600E CRCs still constitute meaningful group of patients (9 to 11 % of patients with mCRC). New therapeutic strategies are urgently needed for those patients. dMMR and BRAF
V600E
are closely interlinked, with specific prognostic and predictive values for both of them. Considering the metastatic setting, new horizons have been opened in the field of dMMR mCRC through immune checkpoint inhibitors, which may be probably the next revolution for patients with dMMR carcinomas. Further studies will have to confirm these attractive results and investigate biological mechanisms underlying sensitivity of dMMR carcinomas to immunotherapy. Dramatic prognosis conferred by BRAF V600E mutation stresses the urge for new therapeutic strategies. Targeting BRAF V600E appears challenging in the context of mCRC and combinations of BRAF inhibitors with other MAPK inhibitors and cytotoxic agents have to be evaluated. For these reasons, patients with dMMR or BRAF V600E mCRC have to be systematically identified because of the potential innovative therapeutic opportunities offered in the ongoing clinical trials.
